This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Intravenous Doxorubicin Nanoparticles for Advanced Hepatocellular Carcinoma

< Back

Intravenous Doxorubicin Nanoparticles for Advanced Hepatocellular Carcinoma


Cancer and Palliative Care

July 2017

Doxorubicin Nanoparticles are an injectable drug made up of microscopic polymer based spheres containing the drug doxorubicin. Doxorubicin, a chemotherapy drug used to treat many types of cancer, slows or stops the growth of cancer cells by blocking an enzyme called topoisomerase 2.2 Studies on doxorubicin nanoparticles on people with advance HCC have suggested it may extend lifespan. If doxorubicin nanoparticles is licenced in the UK, it could provide a new treatment option for patients with advance HCC when other treatment options have failed, which may extend patient survival time.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts